Where Billions in Federal Opioid Grants Go

Last updated 7 days ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

Since the opioid crisis was declared a national public health emergency in October 2017, Congress has allocated tens of billions of dollars to combat an epidemic that has claimed more than half a million lives since the turn of the century.

This financial response flows through federal grants designed to support states, tribes, and local communities on the front lines of the overdose crisis. But where, exactly, does this money go?

In This Article

• The article outlines the flow of federal dollars through major grant programs aimed at addressing the opioid crisis—particularly the State Opioid Response (SOR) Grants and Tribal Opioid Response (TOR) Grants administered by Substance Abuse and Mental Health Services Administration (SAMHSA).
• It highlights that since FY 2018, about $8.1 billion has been awarded through SOR and about $307.5 million through TOR.
• The article points out that despite large funding volumes, there are significant weaknesses: for example, SAMHSA does not collect detailed data on the “ultimate recipients” (sub‑grantees) of these funds, which limits transparency and accountability.
• It describes how states and tribes use the funds: treatment for opioid use disorder, distribution of overdose‑reversal medications (e.g., naloxone), recovery support services, and harm reduction activities.
• The article also mentions emerging directions: grant funds increasingly target polysubstance use (beyond opioids) and place greater emphasis on supporting recovery and addressing stimulant‑involved overdoses. (See FY 2025 continuation funding announcement.)

So What
The scale of federal investment—billions of dollars—is unmistakable and shows the government’s commitment to tackling the overdose crisis. But the lack of granular tracking of where the money lands and how effectively it’s used raises serious accountability concerns. Without better data on sub‑recipient spending and outcomes, it’s hard to know which interventions are working, where gaps remain, and how to refine strategy. The shift toward addressing stimulants and supporting recovery signals a needed evolution in funding prioritisation. For policymakers, funders, and advocates, this means two things: (1) ensure transparency and measurement mechanisms are strengthened to maximise impact; and (2) recognise that what worked in an opioid‑dominant era may not be enough today—data‑driven adaptation is key.

The Federal Architecture

The flow of federal dollars aimed at the opioid crisis originates not from a single source but from a complex architecture of legislation and a network of government agencies. This framework was built incrementally over several years as the scale of the public health disaster became undeniable.

The Legislative Foundation

The federal financial response did not emerge fully formed. It was constructed piece by piece through several key pieces of legislation, each passed as the nature of the epidemic shifted from prescription pill misuse to the dominance of illicitly manufactured fentanyl.

The crisis traces its roots to the mid-1990s, when aggressive marketing of prescription opioids like OxyContin, coupled with regulatory failures at the FDA, ignited the first wave of addiction and overdose deaths. For years, the federal response was fragmented.

A pivotal moment came in 2016 with the passage of the 21st Century Cures Act. This landmark law established the “Account for the State Response to the Opioid Abuse Crisis” in the U.S. Treasury, authorizing $1 billion over two years. This authorization gave birth to the State Targeted Response (STR) to the Opioid Crisis grant program, the first major, dedicated funding stream specifically for this public health emergency.

Administered by the Substance Abuse and Mental Health Services Administration, the STR grants were designed to supplement state activities by increasing access to treatment, reducing unmet needs, and preventing overdose deaths.

That same year, Congress also passed the Comprehensive Addiction and Recovery Act. This legislation authorized a suite of programs aimed at creating a more holistic response spanning prevention, law enforcement, treatment, and recovery. A key creation was the Comprehensive Opioid Abuse Program, managed by the Department of Justice’s Bureau of Justice Assistance. This program was later expanded and renamed the Comprehensive Opioid, Stimulant, and Substance Use Program to reflect the evolving, polysubstance nature of the crisis.

The federal response was supercharged in 2018 with the SUPPORT for Patients and Communities Act. This sweeping law reauthorized and expanded numerous programs and represented the largest single legislative investment, authorizing nearly $9 billion in spending.

Critically, it marked the transition from the initial STR grant program to the much larger and more robust State Opioid Response (SOR) grant program, which remains the primary vehicle for federal opioid funding today.

The Key Federal Players

The billions of dollars authorized by Congress do not flow directly to communities. Instead, they are channeled through a network of federal departments and agencies, each with a distinct mission and portfolio of grant programs.

The Department of Health and Human Services is the undisputed center of gravity for the federal public health response, administering over 75% of all opioid-related appropriations. Within HHS, several key agencies manage the largest funding streams:

Substance Abuse and Mental Health Services Administration: As the lead federal agency for behavioral health, SAMHSA is the single most important player in distributing opioid-related funds. It manages the largest grant programs, including the State Opioid Response grants, Tribal Opioid Response grants, and the foundational Substance Use Prevention, Treatment, and Recovery Services Block Grant. Since 2018, SAMHSA has awarded over $8.4 billion through the SOR and TOR programs alone.

Centers for Disease Control and Prevention: The CDC’s role centers on public health surveillance and prevention. Following the Consolidated Appropriation Act of 2018, the CDC awarded $155 million to states and territories to scale up prevention activities, improve data collection, and advance understanding of the epidemic.

National Institutes of Health: The NIH leads the federal research response. In 2018, it launched the Helping to End Addiction Long-term Initiative, a massive undertaking that has invested over $2 billion into approximately 600 research projects nationwide aimed at developing new, science-based solutions to the crisis.

Health Resources and Services Administration: HRSA focuses on bolstering the healthcare workforce needed to combat the crisis, particularly in underserved rural areas. It provides funding to enhance the behavioral health workforce and supports programs like the Rural Communities Opioid Response Program, which helps expand access to Medication-Assisted Treatment.

While HHS manages the public health response, the Department of Justice oversees the public safety and law enforcement components, working to reduce the trafficking and diversion of illicit opioids.

Bureau of Justice Assistance: The BJA administers the COSSUP grant program, which is designed to help states, local governments, and tribes integrate their public safety and public health efforts. COSSUP funds are often used for innovative programs like law enforcement-led diversion, which connects individuals to treatment instead of jail.

Drug Enforcement Administration: The DEA’s role involves regulating the legal supply chain of opioids and leading law enforcement efforts to disrupt the trafficking of illicit substances like fentanyl.

Finally, the Department of Labor addresses the economic fallout of the crisis. Through its National Dislocated Worker Grants, the DOL provides funding for reemployment services for individuals whose careers have been impacted by substance use.

This multi-agency approach creates a complex and sometimes overlapping patchwork of funding opportunities. A single state might apply for a SAMHSA SOR grant to fund treatment centers, a BJA COSSUP grant to establish a drug court, and a DOL grant to retrain peer recovery coaches.

While this allows for specialization, it also necessitates significant administrative capacity at the state and local levels simply to navigate the federal bureaucracy. This fragmentation was a key finding of a 2019 Bipartisan Policy Center report, which noted a “substantial need for improved coordination of grant programs at the federal level” to reduce the burden on states and improve efficiency.

The Major Grant Programs

While dozens of smaller federal programs touch on the opioid crisis, the bulk of the funding flows through a few major grant programs, each with a distinct purpose and mechanism.

State and Tribal Opioid Response Grants

This is the flagship program and the largest single source of direct funding for the opioid crisis. Administered by SAMHSA, SOR grants are non-competitive, meaning states receive funds based on a formula rather than having to compete for them.

The grants provide highly flexible funding that can be used across the full continuum of care, including prevention, harm reduction, treatment, and recovery support services. Since FY2019, annual appropriations for the SOR program have consistently hovered around $1.5 billion. For Fiscal Year 2024, the total funding was $1.575 billion.

A portion of this funding is specifically set aside for tribes through the Tribal Opioid Response grants. This set-aside, which began at $50 million and has grown to around $63 million, is distributed to federally recognized tribes and tribal organizations to develop and implement culturally appropriate responses to the crisis in their communities.

Substance Use Prevention, Treatment, and Recovery Services Block Grant

Formerly known as the Substance Abuse Prevention and Treatment Block Grant, this is a foundational funding stream from SAMHSA that has existed for decades. It provides states with flexible, reliable funding to support their entire public behavioral health safety net, addressing all substance use issues, not just opioids.

While not exclusively an opioid grant, it is a critical source of long-term, sustainable funding that states use to maintain their core treatment and prevention infrastructure. The SUPTRS Block Grant has been funded at approximately $2 billion annually in recent years.

Comprehensive Opioid, Stimulant, and Substance Use Program

This is the Department of Justice’s primary grant vehicle for the crisis. Unlike the formula-based SOR grants, COSSUP provides competitive, site-based grants to states, local governments, and tribes.

Its unique focus is on fostering collaboration between public health, behavioral health, and public safety systems. COSSUP funding is designed to be flexible, allowing communities to develop innovative programs that align these different sectors, such as pre-arrest diversion programs or teams that embed social workers with law enforcement.

Evolution of the Programs

The structure and naming of these grants reveal a federal response that is both reactive and constantly evolving. The initial State Targeted Response grants of 2016 were replaced by the broader State Opioid Response grants in 2018.

By FY2020, as the crisis on the ground was increasingly characterized by the co-use of opioids and stimulants, the appropriation language for SOR grants was officially amended to allow funds to be used for stimulants like methamphetamine and cocaine. This evolution reflects a continuous effort by Congress and federal agencies to adapt the funding framework to the grim realities of a rapidly changing drug supply.

However, this reactivity means the funding architecture often lags behind the crisis, forcing states to fit their emerging needs—such as a surge in xylazine or methamphetamine—into a framework that was originally designed around opioids.

The Allocation Formula

Once Congress appropriates the money, federal agencies like SAMHSA are tasked with a critical question: how to divide billions of dollars among 50 states, multiple territories, and hundreds of tribal nations? The answer lies in complex allocation formulas designed to direct resources to the areas of greatest need.

The SOR Formula

The State Opioid Response grants, as the largest funding stream, are distributed through a non-competitive formula. This means states are entitled to a certain amount of funding based on objective criteria, a system that provides predictability and avoids the resource-intensive process of competitive grant applications.

The original formula, established with the first SOR grants in 2018, was based on an equal weighting of two key factors intended to measure the severity of the opioid crisis in each state:

Unmet Treatment Need: The state’s proportion of the national total of individuals with opioid use disorder who need but do not receive treatment. This data is derived from SAMHSA’s own National Survey on Drug Use and Health.

Overdose Mortality: The state’s proportion of the national total of drug poisoning deaths, using data from the Centers for Disease Control and Prevention.

A crucial element of this formula is the 15% set-aside. This provision mandates that 15% of the total annual SOR appropriation is reserved for the ten states with the highest mortality rates from drug overdoses. This mechanism ensures that a significant boost in funding is directed to the states at the epicenter of the overdose crisis.

For example, a 2021 SAMHSA report identified the recipients of this set-aside as West Virginia, Delaware, Maryland, Pennsylvania, Ohio, New Hampshire, the District of Columbia, New Jersey, Massachusetts, and Kentucky.

While this formula-based system is intended to be objective, it is not static. A 2024 report from the Government Accountability Office noted that SAMHSA had recently revised its allocation methodology to “better account for State and Tribe Needs.” This revision was prompted in part by concerns from Congress that the original formula could create sharp “funding cliffs,” where a state that saw a small improvement in its mortality rate could fall out of the top ten and lose substantial funding.

However, the use of a formula, while ensuring a predictable distribution of funds, presents a double-edged sword. The national data on which the formula relies, such as CDC mortality statistics, is often one to two years old by the time funding decisions are made. In the current era of a rapidly evolving and increasingly toxic illicit drug supply, the overdose landscape in a state can change dramatically in a matter of months.

This inherent data lag means the formula may be directing the most resources to yesterday’s hotspots rather than today’s emerging crises.

The Tribal Formula Challenge

The funding allocation for the Tribal Opioid Response program operates on a different model, reflecting the unique political status of tribal nations and the distinct challenges they face. The TOR program is funded through a 5% set-aside from the larger SOR appropriation.

Unlike the state formula, which is based on need-based metrics, TOR funds have historically been distributed based on user population estimates from the Indian Health Service. This approach has been heavily criticized by tribal leaders. They argue that using raw population numbers fails to account for the disproportionately severe impact of the opioid crisis in many Native communities and can disadvantage smaller tribes that may have more acute need for services.

American Indian and Alaska Native people have some of the highest overdose death rates of any racial or ethnic group in the country, a reality not captured by a simple population count.

The core of this problem lies in data. As a SAMHSA report on its consultations with tribal leaders bluntly stated, “There is no national data source that shows accurate and complete opioid use/overdose rates for Tribal communities.”

This is not merely a technical issue; it touches on fundamental principles of data sovereignty and reflects a long history of inadequate federal data collection in Native communities. Without reliable, consistent, and culturally appropriate data, creating a truly needs-based formula is nearly impossible.

In response to these criticisms and a mandate in the 2023 Consolidated Appropriations Act, SAMHSA has been working to develop a new formula that gives preference to tribes with demonstrated need for services. Tribal leaders have suggested alternative models, such as providing a base amount of funding to all tribes with the option for supplemental grants, or moving away from a traditional grant structure altogether in favor of a contracting model that would afford them greater flexibility and autonomy.

Where the Money Goes

Once federal grant money reaches the states, territories, and tribes, it is put to work funding a vast array of programs and services. While each jurisdiction tailors its spending to local needs, the grant guidelines and the nature of the crisis have led to common categories of investment across the country.

Treatment Expansion

The central mandate of the State Opioid Response grant program is to expand access to evidence-based treatment for opioid use disorder, with a particular and required emphasis on Medications for Opioid Use Disorder, also known as Medication-Assisted Treatment. This is considered the standard of care for OUD.

Federal grant funds are used to pay for the full spectrum of treatment services. Allowable costs include the three FDA-approved medications—methadone, buprenorphine, and naltrexone—as well as the salaries of the clinical and support staff needed to deliver care, such as physicians, nurses, counselors, case managers, and peer support specialists.

States have used this funding to create new and innovative access points for treatment, especially in underserved areas. Common models include:

The “Hub and Spoke” Model: This model, pioneered in Vermont, establishes regional centers of expertise, often opioid treatment programs, that provide complex care and support a network of community-based providers, such as primary care offices, that offer ongoing MOUD in a less specialized setting.

The “Bridge Clinic” Model: This approach focuses on initiating MOUD in hospital emergency departments. When a person presents in the emergency department after an overdose or seeking help for their substance use, they can be started on buprenorphine immediately and given a “warm handoff” or direct connection to an outpatient clinic for continuing care. California’s Bridge Program is a prominent example, having expanded this model to over 200 hospitals.

Funding is often specifically targeted to populations that have historically had limited access to care, such as individuals in rural areas, people involved in the criminal justice system, and pregnant and postpartum women.

Harm Reduction

Recognizing that the immediate priority is to keep people alive, a significant portion of federal funding is dedicated to harm reduction strategies. These are practical, evidence-based interventions designed to reduce the negative health consequences associated with drug use.

Naloxone Distribution: This is a cornerstone of the national response. SOR funds are widely used to purchase and distribute naloxone, often known by the brand name Narcan, the medication that can rapidly reverse an opioid overdose. States have established massive distribution programs to get naloxone into the hands of first responders, community organizations, schools, libraries, and the general public.

States like California and Washington have state-run Naloxone Distribution Projects that are supported by a blend of federal SOR grants, state funds, and opioid settlement money.

Syringe Services Programs: These community-based programs provide access to sterile syringes and injection equipment to prevent the transmission of infectious diseases like HIV and hepatitis C. While federal funds from HHS can be used to support the operational costs of SSPs—such as staffing, outreach, testing, and linkage to treatment—a long-standing federal law explicitly prohibits the use of these funds for the purchase of the needles or syringes themselves.

This prohibition, a remnant of past political battles, creates a significant practical hurdle for SSPs, forcing them to seek separate, often less stable, funding sources for their most essential supplies.

Fentanyl and Xylazine Test Strips: As the illicit drug supply has become increasingly contaminated with highly potent synthetic substances, drug-checking has become a critical harm reduction tool. In a significant policy shift, SAMHSA and the CDC now explicitly permit federal grant funds—including SOR, TOR, and the SUPTRS Block Grant—to be used for the purchase and distribution of fentanyl test strips and, more recently, xylazine test strips.

This allows people who use drugs to test their substances for the presence of dangerous additive adulterants before consumption.

Prevention and Education

A portion of federal funding is dedicated to primary prevention efforts aimed at stopping substance use disorder before it begins.

Public Awareness Campaigns: States use grant funds to develop and launch statewide media campaigns to educate the public about the dangers of fentanyl, promote the safe storage and disposal of prescription medications, and work to reduce the stigma associated with addiction and treatment.

Youth-Focused Programs: Many prevention efforts are targeted at young people. This includes funding for evidence-based prevention curricula in schools and support for alternative programs like Teen Courts, which provide a therapeutic alternative to the traditional justice system for youth with low-level offenses.

Prescription Drug Monitoring Programs: The Department of Justice, through its Harold Rogers PDMP Grant, provides funding to states to establish and enhance these statewide electronic databases. PDMPs track all prescriptions for controlled substances, allowing prescribers and pharmacists to identify patients who may be receiving prescriptions from multiple doctors and to make more informed clinical decisions.

Recovery and Re-entry

Recognizing that treatment is only the first step, federal grants also support a range of services designed to help people build and sustain long-term recovery.

Peer Recovery Support Services: This has become a major area of investment. SOR and other grants are used to train and employ certified peer recovery specialists—individuals with their own lived experience of substance use and recovery. These peers provide invaluable mentoring, emotional support, and practical assistance in navigating the complex systems of care.

Recovery Housing: Stable housing is a critical component of recovery. Grant funds can be used to support transitional or recovery housing, which provides a safe, substance-free living environment for people leaving treatment or incarceration.

Workforce Development: Beyond just the behavioral health field, the Department of Labor’s Opioid Response Grants focus on helping individuals impacted by the crisis re-enter the workforce. This includes job training, placement services, and supportive employment programs.

Justice System Integration

A significant evolution in the response to the opioid crisis has been the growing recognition that it is a public health issue, not solely a criminal justice one. Federal grants are increasingly used to fund programs that integrate these two systems.

Diversion Programs: The BJA’s COSSUP grants are a key source of funding for pre-arrest or post-arrest diversion programs. These programs give law enforcement officers the discretion to divert individuals who commit low-level, non-violent drug offenses away from jail and directly into treatment and community-based services.

Treatment in Jails and Prisons: Overdose risk is exceptionally high in the period immediately following release from incarceration. To combat this, states are increasingly using SOR and COSSUP funds to provide MOUD to individuals while they are in jail or prison. This not only saves lives but also helps ensure continuity of care as individuals re-enter the community.

Quick Response Teams: These innovative teams often represent a partnership between law enforcement, emergency medical services, and peer recovery specialists. Following a non-fatal overdose, a QRT will visit the survivor within 24 to 72 hours to offer support, provide naloxone, and connect them with treatment options.

Beyond funding direct services, a growing portion of federal grant money is being used to build the “connective tissue” of the response system. Programs like COSSUP are explicitly designed to “facilitate strategic and cross-system planning.” The funding of QRTs and Hub and Spoke models is not just about providing a service but about building new collaborative infrastructure between historically siloed systems like public health, public safety, and social services.

Measuring the Impact

With billions of dollars flowing from the federal government to states and communities each year, the critical question becomes: what is the return on this investment? Measuring the impact of such a massive and decentralized public health effort is extraordinarily complex.

National Outcomes

At a national level, the outputs funded by the State Opioid Response grants are staggering. A 2023 impact brief from the National Association of State Alcohol and Drug Abuse Directors, which aggregates data reported by states, provides a cumulative snapshot of what the grants have accomplished since their inception in 2018.

A 2021 report from SAMHSA to Congress echoed these positive findings, noting that an analysis of client-level data showed tangible improvements in the lives of those served by the grants. Among program participants, there were reported increases in social connectedness, employment, and housing stability, alongside decreases in the use of alcohol and illegal drugs and fewer reported mental health symptoms like depression and anxiety.

Source: National Association of State Alcohol and Drug Abuse Directors 2023 State Opioid Response Grants Impact Brief

While these numbers are impressive, they primarily measure outputs—the volume of services delivered—rather than long-term health outcomes. The ultimate goal is not just to distribute naloxone kits but to reduce the number of people who die from overdoses.

On that front, the national picture is more complex. A report from the Congressional Budget Office noted that while federal funding to address the crisis has increased significantly, overall opioid overdose mortality also continued to increase for much of the grant period, driven largely by the proliferation of illicit fentanyl.

This creates a difficult paradox: the programs are clearly engaged in a massive amount of life-saving activity, but they are fighting against a tide of an increasingly toxic drug supply.

The Government Accountability Office has pointed to this gap between outputs and outcomes, characterizing SAMHSA’s national reports as “high-level national snapshots” and recommending that the agency conduct more in-depth analysis to better understand why certain programs are or are not working.

State Examples

The national data obscures the wide variation in how states are implementing their opioid response. A closer look at individual states reveals diverse strategies tailored to unique local contexts, demographics, and political environments.

Ohio: A Decentralized Approach

As one of the states hardest hit by the crisis, Ohio has been a top recipient of SOR funds, receiving approximately $97 million in FFY23 and $100 million in FFY24. The Ohio Department of Mental Health and Addiction Services employs a highly decentralized strategy for its “State Opioid and Stimulant Response” initiative.

The majority of the funds—over $58 million from a recent $100 million award—are channeled directly to the state’s 50 county-level Alcohol, Drug Addiction, and Mental Health Services boards. This model empowers local communities to design and implement programs that address their specific needs.

This local control has led to a wide array of funded projects, including Quick Response Teams, naloxone vending machines, peer support services in local jails, and specialized care for infants born with substance exposure. The state’s definition of allowable expenses is notably broad, covering not only direct treatment but also supportive services like work boots for participants in vocational programs and car seats for the children of parents in treatment.

Ohio has reported positive trends, with a 9% decline in overdose deaths in 2023, a rate that significantly outpaced the national average.

West Virginia: Crisis Response

Consistently leading the nation in overdose mortality, West Virginia has received a massive infusion of federal aid, totaling $248 million in SOR funds from FY18 to FY23. The state’s Bureau for Behavioral Health directs this funding toward a comprehensive continuum of care, from youth prevention programs like Teen Court to intensive harm reduction and treatment initiatives designed for a state in acute crisis.

Key state-funded initiatives include the provision of MOUD in all ten of its regional jails, the deployment of mobile treatment units to reach isolated rural populations, the establishment of QRTs in the highest-need communities, and a robust statewide naloxone distribution network.

However, West Virginia’s implementation has been plagued by significant challenges. A scathing 2024 audit by the HHS Office of Inspector General found that the state “lacked effective oversight” of its grants, was unable to provide documentation to support its own progress reports, and failed to adequately monitor how its subrecipients were spending the money.

This highlights a critical gap between receiving funds and having the administrative capacity to manage them effectively.

California: An Equity-Focused System

California has received hundreds of millions in SOR funds, including $176.1 million from FY18 to FY20 alone. The state’s Department of Health Care Services has developed a sophisticated model that strategically braids these federal SOR grants with state general funds and the state’s substantial share of national opioid settlement awards.

A central pillar of California’s strategy is addressing health inequities. Programs are specifically designed to target services to populations that have been disproportionately impacted, including Black, Tribal/Urban Indian, Hispanic/Latinx, and LGBTQI+ communities, as well as youth and people experiencing homelessness.

Signature programs include the California Bridge Program, which has successfully integrated MAT into over 200 hospital emergency departments; the Youth Opioid Response California project, which funds a wide range of youth-focused services; and the massive statewide Naloxone Distribution Project.

An analysis of how California is spending its state-level settlement funds—which complements its SOR grant activities—shows a clear prioritization of investments in workforce training ($51.1 million), naloxone distribution ($15 million), and youth opioid education campaigns ($40.8 million).

Source: Data compiled from NASADAD State Briefs

These state spotlights reveal that there is no single playbook for spending federal opioid grants. The federalist structure of the grant programs allows for—and even encourages—this diversity of approaches. However, it also complicates efforts to determine which strategies are most effective on a national scale.

Challenges and Oversight

While federal grants have enabled a massive expansion of life-saving services, the process of distributing and spending these billions is fraught with friction. Reports from government watchdogs like the Government Accountability Office and the HHS Office of Inspector General, along with criticisms from stakeholders on the ground, reveal systemic challenges related to accountability, administrative capacity, and strategic alignment.

Government Watchdog Findings

Federal oversight bodies have conducted numerous audits and reviews of the opioid grant programs, and their findings point to several recurring problems.

The Unspent Funds Problem: One of the earliest and most striking findings came from a 2020 OIG report on the initial State Targeted Response grants. It found that nearly a third of the program’s funding—over $300 million—remained unspent by states after the two-year grant period had ended. Fourteen states had spent less than half of their allocation.

The primary reason cited by states was not a lack of need, but rather delays caused by their own internal procurement and contracting processes, which were too slow and cumbersome to handle a rapid influx of emergency funding. As a result, all but six states had to request no-cost extensions of up to a year just to spend the money they had already been awarded.

The “Ultimate Recipient” Problem: Perhaps the most persistent criticism, raised repeatedly by the GAO, is SAMHSA’s failure to collect data on the “ultimate recipients” of its grant funds. The current system works like this: SAMHSA provides a large block grant to a state agency. That state agency then sub-awards the money to dozens or even hundreds of local providers—non-profits, community health centers, county health departments, and others.

The GAO has found that SAMHSA does not track who these final subrecipients are. This creates a critical data black hole. Without knowing precisely which organizations on the ground are receiving the money, it is impossible for the federal government to conduct a meaningful evaluation of which local programs are most effective or to identify best practices that could be replicated elsewhere.

Inadequate State Oversight: Even when data is collected, its quality and reliability can be questionable. OIG audits of individual states have uncovered significant failures in oversight. The 2024 audit of West Virginia found that the state “lacked effective oversight,” could not provide documentation to support the outcomes claimed in its annual progress reports, and did not adequately monitor the spending of its subrecipients.

Similarly, a 2025 OIG audit of Florida found that the state submitted inaccurate federal financial reports and could not fully support its reported outcomes for key program goals. These are not isolated incidents; they point to a systemic challenge where state agencies may lack the capacity, procedures, or rigor to effectively manage and account for the massive influx of federal funds.

Barriers for Tribes: The GAO has also highlighted specific challenges faced by tribal nations. In its 2024 report, the GAO found that “grant-related administrative challenges contribute to some Tribes not participating or not making full use of TOR” grants. These burdens, from complex application processes to stringent reporting requirements, can be overwhelming for smaller tribal governments with limited administrative staff.

The structure of the federal block grant model is at the heart of this accountability gap. By design, these grants give states immense flexibility to tailor their responses. However, this same structure inherently limits the federal government’s visibility and control.

SAMHSA’s primary role is to distribute money to states based on a formula; it is not equipped to micromanage the public health departments of over 50 states and territories. But without a reliable stream of high-quality data flowing up from the local level, a true national-level evaluation of the multi-billion-dollar investment remains out of reach.

Strategic Debates

Beyond the operational challenges identified by government auditors, there are broader strategic debates about how the money is being used and whether the overall approach is the right one.

The Supplantation Issue: A major concern, particularly as opioid settlement funds also become available, is the risk of “supplantation.” This occurs when a state or local government uses new federal or settlement money to pay for existing programs or staff salaries, rather than to fund new or expanded services.

This allows the government to then shift its own state or local funds, which were previously paying for those programs, to fill other budget holes unrelated to the opioid crisis. While not always explicitly prohibited, this practice undermines the goal of the new funding, which is to supplement, not replace, existing efforts.

Allocation Equity and the Evolving Crisis: As the overdose crisis has morphed from one driven by prescription opioids to one dominated by illicit fentanyl and, increasingly, stimulants like methamphetamine, critics question whether the funding formulas and program names are keeping pace.

Although SOR funds can now be used to address stimulant use, the allocation formula that determines how much money each state gets is still based primarily on opioid-related metrics. This could potentially disadvantage a state that is experiencing a severe methamphetamine crisis but has a comparatively lower opioid mortality rate.

Treatment vs. Supply Reduction: While the vast majority of HHS-administered grant funding supports public health approaches like treatment, prevention, and harm reduction, there is an ongoing national debate about the proper balance between these “demand reduction” strategies and “supply reduction” efforts like law enforcement and border interdiction.

Some research indicates that community stakeholders and people with lived experience of drug use would prioritize funding for treatment and harm reduction far more heavily, and allocate significantly less to law enforcement and supply-side interventions, than current government budgets reflect.

The challenges in implementing the federal opioid grants are not new problems created by the crisis. Instead, the massive influx of funding has thrown a harsh spotlight on the pre-existing weaknesses in America’s public health infrastructure.

State and local health departments, after decades of being underfunded, were suddenly asked to manage an unprecedented public health emergency and administer billions of dollars in new funding. Their struggles with slow procurement, inadequate data systems, and workforce shortages are symptoms of a system that was already strained to its breaking point.

In many ways, the federal grants are being asked to do two things at once: fight the deadliest overdose crisis in the nation’s history, and simultaneously rebuild the public health system needed to win that fight.

Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.